About Immunomedicor
Our Mission
Our mission is the development of superior products and services to prolong and improve the quality of human life with the following values:
1) To sustain, improve and prolong human life to the best state it can be.
2) Develop non-toxic drug candidates and assure that our drug candidates have very few, if any, negative side effects.
3) To be one of the major factors in a holistic approach to human health.
4) To gain profit from our ventures, but not at the cost of our employees, customers, community or environment. We seek to attract investment in our ventures, so we must maintain the higest possible level of integrity in our business affairs. We are honest and we go beyond our own and other organizations call of duty to follow the spirit and letter of the law in all our business dealings.
5) To intially attract on a voluntary basis and later upon further funding to retain highly motivated employees.
6) Build a company which is a strong part of its employee’s quality of life and career success. We encourage our employees diversity and respect others opinions and ideas. Above all we want to foster an open "think tank" type of environment so that we achieve our higest research goals.
7) To support our employees and indirectly their families and assure their success in a transparent manner. We are continually seeking to improven the teamwork, skill and knowledge of our employees and communities.
8) To engage in business with the higest standards of science, ethics and integrity. We follow the laws of the pharmaceutical industry and assure that our employees do the same. We do the best that we can to work smart and hard, but we more value preserving our employee's family life. We also preserve our customers, commmunities and envrionment.
|
|
| 1. On initial funding we will complete a research grant to improve
the process by which the IM-039 is separated from its raw material.
We will also sign the lease on the laboratory facility and begin
installation of the equipment critical to the separation and characterization
of the IM-039 from its raw material. Timing: first 30 days. 2. In approximately 30 days from the lease signing, we should have the first sections of the lab operational and ready to begin the process of separation and characterization of the IM-039 from its raw material. Timing: 30 days 3. After about four weeks of work on the separation, we should
have enough working material to begin the first stages of the preclinical
work. 4. Small amounts of the IM-039 will be shipped to a contract facility
to begin the humanization of IM-039. 5. After roughly 15 weeks of development, the humanized version
of IM-039 will be ready for testing for toxicity, affinity and
effectiveness. 6. One week after completion of the humanized IM-039, we should
be ready to file for patents in both the US and Mexico. 7. Immediately following the filing of the patent applications,
we will begin in vitro testing of the IM-039 against various cancer
lines. 8. After approximately 30 days, we should be able to start our
preclinical small animal studies. 9. Once we have concluded the small animal studies, we should
be able to file our “Innovative New Drug” (IND) application
with the FDA. 10. As we conclude our small animal studies and show no toxicity
and good affinity plus effectiveness, we may begin clinical trials
in a foreign country. |
